Of the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb. The remaining five assets will be jointly discovered.

Original title: “BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal”

Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?

Original title: “A year after Vertex’s big launch, pain drug research faces a pivotal moment”

The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access to a therapy called bepirovirsen that’s important to its future.

Original title: “GSK cuts deal with Sino to broaden reach of hepatitis B drug”

BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing.

Original title: “Biotech layoffs are easing, but is the worst over?”

Partner Therapeutics announced last week that the FDA had granted Bizengri a Commissioner’s National Priority Voucher to accelerate drug review.

Original title: “Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher”

The future of medicine is here. See how specialized logistics are saving lives with next-gen cell and gene therapies.

Original title: “Precision in motion: Decoding the critical operations behind the logistics of next-generation cell and gene therapies”

Cell and gene therapies aren’t limited by ideas—they’re limited by where they’re built. See how “ready-now” locations change the math on scaling.

Original title: “The capacity crunch in biopharma is a location problem”

New guidelines from two leading medical associations suggest that efforts to reduce bad cholesterol should focus on maintaining low levels of two key lipoproteins. Big pharma is all in, looking to improve on the standard statins to help vanquish America's number one killer: heart disease.

Original title: “Merck, Amgen double down on bad cholesterol to vanquish number 1 killer”

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is actively seeking potential licensees interested in further developing these inhibitory transmembrane adapter proteins as targets for T-cell immunotherapy for the treatment of cancer, infectious diseases, and autoimmune diseases.

Original title: “Government Owned Inventions Available for License: Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1”

The Indianapolis-based company expanded its spend to ensure it can meet growing demand for its weight-loss drugs.

Original title: “Lilly to invest extra $4.5B across Indiana manufacturing”

Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.

Original title: “Lilly, Gilead lead pharma’s M&A boom”